Do you want to read an article? Please log in or register.
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
Lancet Gastroenterol Hepatol
Jairath V, Kierkuś J, Duvall GA, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Reinisch W
doi: 10.1016/S2468-1253(26)00119-6
Inflammatory Bowel Disease
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group
doi: 10.1016/S2468-1253(25)00322-X
Inflammatory Bowel Disease
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Lancet Gastroenterol Hepatol
Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group
doi: 10.1016/S2468-1253(25)00198-0
RECOMMENDED
Gastrointestinal Diseases
Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Adv Ther
Peyrin-Biroulet L, Seenan JP, Armuzzi A, Lazar A, Eldred A, Doan T, Polakow SB, Al Mahi N, Liu M, Nader A, Bhatnagar S, Schreiber S
doi: 10.1007/s12325-026-03517-3
Inflammatory Bowel Disease
Placebo rates in randomised clinical trials of ulcerative colitis: An individual patient data meta-analysis
J Crohns Colitis
Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Vuyyuru S, Macdonald JK, Zou G, Yuan Y, Sands BE, Panaccione R, Feagan BG, Hanzel J, Sedano R, Dulai P, Narula N, Ma C, Jairath V
doi: 10.1093/ecco-jcc/jjaf191
Gastritis
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial
Lancet Gastroenterol Hepatol
Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators
doi: 10.1016/S2468-1253(26)00116-0
Inflammatory Bowel Disease
Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials
Inflamm Bowel Dis
Wong ECL, Marshall JK, Ma C, Jairath V, Reinisch W, Narula N
doi: 10.1093/ibd/izag054
Inflammatory Bowel Disease
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
Clin Gastroenterol Hepatol
Danese S, Goetsch M, Peyrin-Biroulet L, Yarur AJ, Dubinsky M, Rubin DT, Feagan BG, D'Haens G, Baert F, Lazin K, Gu G, Yu J, Lawendy N, Zang C, Wang W, Menon S, Law EH, Modesto I, Wosik K, Sidhu S, Niezychowski W, Vermeire S
doi: 10.1016/j.cgh.2026.05.024
Gallbladder and Biliary Diseases
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C, GLISTEN Study Group
doi: 10.1016/S2468-1253(25)00192-X